Spyre Therapeutics (SYRE) Other Non Operating Income (2015 - 2026)

Spyre Therapeutics has reported Other Non Operating Income for 12 years, with the latest figure at -$30.4 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non Operating Income fell 1428.04% year-over-year to -$30.4 million; the trailing twelve-month figure through Mar 2026 stood at -$3.2 million (up 82.24% YoY), and the FY2025 full-year result was $29.5 million, up 242.22% from the prior year.
• Other Non Operating Income for Q1 2026 stood at -$30.4 million, down from -$12.5 million in the prior quarter.
• The five-year high for Other Non Operating Income was $40.3 million in Q3 2025, with the low at -$30.4 million in Q1 2026.
• Historically, Other Non Operating Income has averaged -$2.4 million across 5 years, with a median of -$72000.0 in 2023.
• The largest YoY upside for Other Non Operating Income was 9658.33% in 2023 against a maximum downside of 66750.0% in 2023.
• Spyre Therapeutics' Other Non Operating Income stood at -$32000.0 in 2022, then plunged by 66750.0% to -$21.4 million in 2023, then surged by 96.18% to -$818000.0 in 2024, then tumbled by 1427.75% to -$12.5 million in 2025, then plunged by 142.93% to -$30.4 million in 2026.
• The last three Other Non Operating Income figures came in at -$30.4 million (Q1 2026), -$12.5 million (Q4 2025), and $40.3 million (Q3 2025), per Business Quant data.